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“Recomeça… 
Se puderes, 
Sem angústia e sem pressa. 
E os passos que deres, 
Nesse caminho duro 
Do futuro, 
Dá-os em liberdade. 
Enquanto não alcances 
Não descanses. 
De nenhum fruto queiras só metade. 
  
E, nunca saciado, 
Vai colhendo 
Ilusões sucessivas no pomar 
E vendo 
Acordado, 
O logro da aventura. 
És homem, não te esqueças! 
Só é tua a loucura 
Onde, com lucidez, te reconheças.” 
 
Miguel Torga, Sísifo in Diário XIII 
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ABSTRACT 
 
Introduction: Intra-abdominal infections represent one of the most frequent gastrointestinal 
emergencies and a serious cause of morbidity and mortality. A full classification that includes all 
facets of intra-abdominal infections does not exist. There are two classifications used to subdivide 
intra-abdominal infections: uncomplicated or complicated, founded on the extent of infection, and 
community-acquired, healthcare-associated or hospital-acquired, based on the place of acquisition. 
The adequacy of the initial empirical antibiotic therapy prescribed is an essential need. There is 
evidence that inadequate and/or delayed antibiotic therapy is associated with treatment failure and 
increased mortality.  
 
Objectives: This study was designed to assess the impact of the different classifications of intra-
abdominal infections in the selection of the best antibiotic therapy. Main objectives of the study are: 
to identify independent factors for intra-abdominal infection by pathogens sensitive to the antibiotic 
scheme recommended for community-acquired intra-abdominal infection: non-pseudomonal 
cephalosporin or ciprofloxacin plus metronidazole (shorter spectrum and main outcome) or 
piperacillin/tazobactam; to describe the microbiological profile associated with each classification; to 
determine the discriminative power of each intra-abdominal infection classification to identify 
patients infected by a pathogen sensitive to the elected antibiotic combination; and to describe 
major prognostic factors associated with hospital mortality among the study population of patients 
with intra-abdominal infection. 
 
Methodology: Retrospective cohort study including all adult patients discharged from the hospital 
with the diagnosis of intra-abdominal infection between 1st of January and 31st of October of 2016. 
All variables potentially associated with pre-defined outcomes were studied through logistic 
regression. The accuracy of the models was assessed by the area under receiver operating 
characteristics curve and calibration was tested using the Hosmer-Lemeshow goodness-of-fit test. 
 
Results: There were 1804 patients initially selected and 154 of these met the inclusion criteria. 
Sensitivity to non-pseudomonal cephalosporin or ciprofloxacin plus metronidazole is associated with 
male gender (adjusted odds ratio (OR) = 2,612) and previous invasive procedures in the last year 
(adjusted OR = 0,424) (area under receiver operating characteristics (AUROC) curve = 0,65). 
When considering sensitivity to piperacillin/tazobactam, there was an association with liver disease 
(adjusted OR = 3,580) and post-operative infections (adjusted OR = 2,944) (AUROC curve = 
0,604). Hospital mortality resulted in an association with age ≥ 70 (adjusted OR = 4,677), solid 
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tumor (adjusted OR = 3,127) and sensitivity to non-pseudomonal cephalosporin or ciprofloxacin 
plus metronidazole (adjusted OR = 0,368).  
 
Conclusions: In this study, none of the existent classifications had a good discriminative power to 
identify intra-abdominal infections caused by pathogens sensitive to the current antibiotic treatment 
recommendations.  
 
Keywords: intra-abdominal infections; classification; antibiotic therapy; hospital mortality. 
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RESUMO 
 
Introdução: As infeções intra-abdominais representam uma das mais frequentes emergências 
gastrointestinais e uma importante causa de morbilidade e mortalidade. Uma classificação que inclua 
todas as caraterísticas das infeções intra-abdominais ainda não existe. Existem duas classificações 
utilizadas para subdividir infeções intra-abdominais: não complicada ou complicada, considerando a 
extensão da infeção, e adquirida na comunidade, associada a cuidados de saúde ou adquirida no 
hospital, baseando-se no local de aquisição. A adequação da antibioterapia empírica inicial prescrita 
é fundamental. Existe evidência que antibioterapia inadequada e/ou extemporânea está associada 
com insucesso terapêutico e mortalidade aumentada. 
 
Objetivos: Determinar o impacto das diferentes classificações de infeção intra-abdominal na 
seleção da melhor antibioterapia empírica. Os objetivos principais do estudo são: identificar fatores 
independentes para infeção intra-abdominal por microrganismos sensíveis à antibioterapia 
recomendada para infeções intra-abdominais adquiridas na comunidade: cefalosporina não anti-
pseudomónica ou ciprofloxacina mais metronidazol (espectro mais curto e objetivo principal) ou 
piperacilina/tazobactam; descrever o perfil microbiológico associado a cada classificação; determinar 
o poder discriminativo de cada classificação na identificação de pacientes infetados por patogéneos 
sensíveis à antibioterapia elegida; e descrever os fatores de prognóstico associados à mortalidade 
hospital na população de doentes com infeção intra-abdominal. 
 
Metodologia: Estudo de coorte retrospetivo incluindo todos os pacientes adultos diagnosticados 
com infeção intra-abdominal, à data de alta, entre 1 de janeiro e 31 de outubro de 2016. Todas as 
variáveis potencialmente associadas com os desfechos pré-definidos foram analisadas através de 
regressão logística. A precisão dos modelos foi estudada através da área debaixo da curva 
característica de operação do recetor e a calibração foi testada pelo teste de Hosmer-Lemeshow. 
 
Resultados: Inicialmente foram selecionados 1804 pacientes e, destes, 154 apresentaram critérios 
de inclusão. A infeção intra-abdominal por patogéneos sensíveis ao esquema de antibioterapia, 
cefalosporina não anti-pseudomónica ou ciprofloxacina mais metronidazol, foi associada de forma 
independente ao sexo masculino (odds ratio (OR) ajustado = 2,612) e a procedimentos invasivos 
no último ano (OR ajustado = 0,424) (area under receiver operating characteristics (AUROC) 
curve = 0,65). Quando testada a sensibilidade a piperacilina/tazobactam, existiu uma associação 
independente com a doença hepática (OR ajustado = 3,580) e as infeções pós-operatórias (OR 
ajustado = 2,944) (AUROC curve = 0,604). A mortalidade hospitalar associou-se de forma 
independente com a idade ≥ 70 (OR ajustado = 4,677), tumores sólidos (OR ajustado = 3,127) e 
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à sensibilidade a cefalosporina não anti-pseudomónica ou ciprofloxacina mais metronidazol (OR 
ajustado = 0,368). 
 
Conclusões: Neste estudo, nenhuma das classificações existentes teve um bom poder 
discriminativo na identificação de infeções intra-abdominais causadas por microrganismos sensíveis 
à antibioterapia atualmente recomendada. 
 
Palavras-chave: infeções intra-abdominais; classificação; antibioterapia; mortalidade hospitalar. 
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INTRODUCTION 
 
Intra-abdominal infections: definition and impact 
 
 Intra-abdominal infections (IAIs) include a large diversity of pathological conditions involving 
inflammatory processes and lesions of all the intra-abdominal organs in response to microorganisms, 
which may spread into the peritoneal space.1-5 They include inflammation of single organs (such as 
cholecystitis, appendicitis, diverticulitis, cholangitis, pancreatitis, salpingitis, etc.), peritonitis (classified 
as primary, secondary or tertiary) and intra-abdominal abscesses (classified by their location and 
anatomic configuration).1, 2, 4, 6 
 IAIs represent one of the most frequent gastrointestinal emergencies and a serious cause 
of morbidity and mortality, especially identified as a cause of severe sepsis in patients in the intensive 
care unit and the second most common cause of infection-related mortality.2, 5, 7-10 
 
 
Centre for Disease Control and Prevention’s definition and criteria 
 
 According to the Surveillance Definitions for Specific Types of Infections of Centre for 
Disease Control and Prevention (CDC), IAIs must match at least one of the following criteria: 
- Identification of organisms from an abscess or purulent material from intra-abdominal space 
by a culture or non-culture based microbiologic testing method which is performed for 
purposes of clinical diagnosis or treatment (e.g., not Active Surveillance Culture/Testing 
(ASC/AST); 
- Patient has abscess or other evidence of IAI on gross anatomic or histopathologic exam;  
- Patient has at least two of the following signs or symptoms: fever (>38.0°C), nausea, 
vomiting, abdominal pain, or jaundice, with no other recognized cause. And at least one of 
the following:  
o organisms seen on Gram stain or identified from drainage or tissue obtained during 
invasive procedure or from an aseptically-placed drain by a culture or non-culture 
based microbiologic testing method which is performed for purposes of clinical 
diagnosis or treatment; 
o organisms identified from blood by a culture or non-culture based microbiologic 
testing method which is performed for purposes of clinical diagnosis or treatment and 
imaging test evidence suggestive of infection, which if equivocal is supported by clinical 
correlation (i.e., physician documentation of antimicrobial treatment for 
intraabdominal infection).11  
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Classifications of intra-abdominal infection 
 
 A broad diversity of patient population is described by the term IAI and a full classification 
that includes all facets of IAIs does not exist.  
 An optimal classification designed for clinicians’ guidance in treatment should include: the 
origin of the source of infection, the anatomical extension, the supposed pathogens involved and 
risk factors for major resistance patterns, and the clinical condition of the patient.3, 5, 10 
 
 
Uncomplicated versus complicated intra-abdominal infections  
 
 IAIs are most frequently subdivided as uncomplicated or complicated, which is often used 
in guidelines and clinical trials, and this classification is founded on the extent of infection.1-6, 10, 12   
 An uncomplicated intra-abdominal infection (uIAI) is an infection that only involves a single 
organ and does not extend to the peritoneum, occurring intramural inflammation of the 
gastrointestinal tract without anatomic disruption.1-6, 8-10, 12-14 Patients with this type of infection can 
be managed with surgical procedures or antibiotic therapy. Acute diverticulitis, acute cholecystitis 
and some acute appendicitis are examples of uncomplicated intra-abdominal infections that can be 
managed non-operatively, using antibiotic therapy,4 but if not properly treated, have an important 
chance of evolving into a complicated intra-abdominal infection (cIAI). 14 
 In situation of a cIAI, the infectious process extends beyond a single organ into the 
peritoneal space, causing peritoneal inflammation, and is associated with localized or diffuse 
peritonitis.1-6, 8-10, 12-14 The treatment of this type of infections should include both surgical and 
antibiotic therapy.4, 12  
 Localized peritonitis is frequently revealed as an abscess, containing tissue debris, bacteria, 
neutrophils, macrophages and exudative fluid enclosed in a fibrous capsule. Diffuse peritonitis is 
afterwards classified as primary, secondary or tertiary peritonitis.1-6, 8-10, 12  
 
 
Primary, secondary and tertiary peritonitis 
 
 Peritonitis is an infection in which the local inflammatory process is provoked by 
microorganisms and can be compared to a sepsis located in the peritoneum.1 It is universally 
accepted to classify peritonitis as primary, secondary or tertiary.  
 Primary peritonitis, additionally known as spontaneous bacterial peritonitis, is a diffuse 
bacterial infection, commonly with mono-microbial etiology, with maintenance of integrity of the 
gastrointestinal tract. The infectious process is thought to be the result of bacterial translocation 
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across an intact gastrointestinal tract and it is regularly detected in cirrhotic patients with ascites, 
patients with an indwelling peritoneal dialysis catheter and in infancy and early childhood.  
 Secondary peritonitis is caused by microbial contamination through a perforation, laceration, 
or necrotic segment of the gastrointestinal tract, and it represents more than 90% of all cases of 
peritonitis. The etiology of the infection is frequently poly-microbial and dependent on the source 
of contamination. Anastomotic dehiscences are common causes of peritonitis in the postoperative 
period.1, 2, 6, 10 Secondary peritonitis with severe sepsis or septic shock have reported an average 
associated mortality rate of approximately 30%.15-18 
 Tertiary peritonitis is described as a recurrent or persistent infection of the abdominal cavity 
that lasts more than 48 hours after allegedly successful and appropriate surgical source control of a 
secondary peritonitis. It occurs more frequently in critically ill or immunocompromised patients, and 
is repeatedly linked to highly resistant pathogens and high morbidity and mortality.1, 2, 6, 10 Despite 
the common use of the term tertiary peritonitis, it reproduces an evolution and complication of 
secondary peritonitis, consequently the term “ongoing peritonitis” may be a better classification for 
this entity.3, 10 
 
 
Community-acquired, hospital-acquired and healthcare-associated intra-abdominal 
infections 
 
 For the sake of a better identification of the pathogens presented and evaluation of related 
resistance patterns, infections are classically divided in community- or hospital-acquired.10, 13, 19, 20 
 A community-acquired intra-abdominal infection (CA-IAI) is an infection present at hospital 
admission or within 48 hours in patients that did not meet the criteria for healthcare-associated 
infection and it is usually caused by the patient’s own flora, including Enterobacteriaceae, viridans 
group Streptococcus and anaerobes (particularly Bacteroides fragilis).4, 7, 10, 13, 14, 19, 20 
 Hospital-acquired intra-abdominal infections (HA-IAIs) are defined as infections that were 
not present at the time of hospital admission but emerge as noticeable after at least 48 hours in 
patients hospitalized for other purpose than IAIs13, 20-22 and are provoked by nosocomial 
microorganisms of specific hospital or unit.19 
 In the last two decades due to the massive development of the outpatient clinical care, the 
addition of a new class was proposed named healthcare-associated infections (HCA-IAIs), for the 
group of infections emerging in patients at the community setting with a recent history of exposure 
to professional healthcare that do not meet the criteria for HA-IAI.23, 24 
 HCA-IAIs are defined as infections present at hospital admission or within 48 hours of 
admission in patients with previous contact with healthcare, namely invasive procedures, or that 
resides in a long-term care facility.13, 23 
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 This new classification is far from being consensual and several risk factors have been 
proposed to be part of it.10, 14, 23 The most accepted criteria includes: intravenous therapy took at 
home, wound treatment or specialized nursing care through a healthcare agency, family or friends; 
or had self-delivered intravenous medical therapy within 30 days previous to the infection; 
attendance to an hospital or hemodialysis clinic or receiving intravenous chemotherapy received 30 
days before; being hospitalized in an acute care hospital for at least 2 days in the past 90 days; or 
inhabited in a nursing home or long-term care facility.10, 23, 24  
 Lately recent invasive procedures, hospitalization in the last year and previous antibiotic 
therapy have been increasingly recognized as major risk factors for infection by resistant pathogens 
among patients arriving from the community with infection.23 
 HCA-IAIs are frequently motivated by higher resistant pathogens, including non-fermenting 
gram-negative Pseudomonas aeruginosa and Acinetobacter species, broad spectrum b-lactamase-
producing Klebsiella species and Escherichia coli, Enterobacter species, Proteus species, methicillin-
resistant Staphylococcus aureus (MRSA) and Enterococci.13, 14, 20, 25-27 In these cases, complex 
multidrug antibiotic therapies are suggested, considering that competent empiric therapy seems to 
be valuable in affecting postoperative complications and mortality.13, 14, 25  
 Antibiotic therapy that neglect to reach possible pathogens in IAIs has been correlated to 
greater treatment failure and mortality,14, 25 being extremely important to choose an antibiotic suited 
to the most probable pathogens according to the individual patient risk factors, including local flora 
at the facilities where the patient has acquired the infection.13 
 
 
Treatment of intra-abdominal infections 
 
 The intervention needed to treat the infection is conditioned by the anatomical location, 
the extent of peritoneal inflammation, the established septic reaction, the patient’s co-morbidities 
and the accessible assets of the treatment centre.4 The success of IAIs’ treatment depends on quick 
and adequate source identification, control and antibiotic therapy.2, 10, 28 
 Source control is any procedure or succession of procedures that remove infectious foci, 
contain elements that support current infection, and regulate or contain anatomic irregularities to 
fix normal physiologic function.2, 6, 10, 14, 29 The failure of it is more expected in patients with 
postponed procedures (> 24 hours), greater gravity of illness (APACHE-II score ³ 15), higher age 
(> 70 years), previous co-morbidities, poor nutritional condition, and a greater extent of peritoneal 
involvement.14 
 IAIs, such as diverticulitis and some types of acute appendicitis, can be handle without a 
surgical procedure. Patients treated without a surgical procedure have a microbiology identical to 
patients treated operatively, and the same antibiotic therapy advocated for patients with cIAIs is 
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proposed.14   
 The initial empirical antibiotic therapy prescribed for IAIs is an essential need,2, 4, 10, 12, 13, 20 
due to the minimum 48 hours’ time required to have microbiological data available (culture and 
susceptibility results). The empirically planed antibiotic regimen is determined by the intrinsic severity 
of infection, the microorganisms assumed to be implicated, and the presence of risk determinants 
suggestive of significant resistance patterns.2, 4, 10, 12 Suitable empiric antibiotic therapy has a huge 
impact on the outcome of patients diagnosed with IAIs.13, 18, 20, 28, 30 
 IAI can be managed with single or combined antibiotic regimens, determined by the 
spectrum demands of antibiotic scope.4, 5, 10, 31 Ampicillin/sulbactam, cefoxitin, ertapenem, 
meropenem, moxifloxacin, ticarcillin/clavulanic acid and tigecycline are examples of antibiotic 
therapy licensed to be used as single agents.10, 14, 31 Third/fourth-generation cephalosporin (cefepime, 
cefotaxime, ceftazidime, ceftizoxime, ceftriaxone) plus an anti-anaerobe, cefuroxime plus 
metronidazole, ciprofloxacin plus metronidazole, aztreonam plus clindamycin and aminoglycosides 
(amikacin, gentamicin, netilmicin, tobramycin) plus an anti-anaerobe are examples of antibiotic 
therapy used as combination regimens.10, 31 
 Infections originating at the stomach, duodenum, biliary system and proximal small bowel 
include gram-positive and gram-negative aerobic and facultative pathogens. Infections originating at 
distal small bowel perforations include gram-negative facultative and aerobic pathogens with diverse 
quantity. IAIs originating at colon shelter facultative and constrain anaerobic pathogens. In addition, 
streptococci, especially the Streptococcus milleri group, and Enterococci are usually present. The most 
consistently discovered gram-negative facultative pathogen is Escherichia coli.2, 6, 14, 32 
 Anticipating the microorganisms and promising resistance patterns of a particular infection 
initiates by determining the place of acquisition of the infection4, 13 (community-acquired, healthcare-
associated or hospital-acquired). 
 In CA-IAI, antibiotics with a restricted spectrum of activity,4, 10, 13, 31 less expensive and less 
toxic are suggested,4, 31 such as second-generation cephalosporins with anaerobic coverage, 
ampicillin/sulbactam and ticarcillin/clavulanic acid.13, 31 Antibiotic therapy regimens like 
cephalosporins without Pseudomonas aeruginosa coverage plus metronidazole, ciprofloxacin plus 
metronidazole, and piperacillin/tazobactam are recommended for the treatment of CA-IAIs.4, 10, 13, 
33 Nevertheless, if CA-IAI patients have previous exposure to antibiotic therapy or severe co-
morbidities involving simultaneous antibiotic therapy, anti-ESBL-producer coverage may be ensured. 
Conversely, in HA-IAIs, antibiotic regimens with vaster spectra of coverage are suggested.4, 10, 12   
 There were reported, in past decades, an augmented prevalence of IAIs caused by 
antibiotic-resistant pathogens,4, 10, 13 such as MRSA, vancomycin-resistant Enterococcus species, 
carbapenem-resistant Pseudomonas aeruginosa, extended-spectrum betalactamase (ESBL)-
producing Escherichia coli and Klebsiella species, and multidrug-resistant Acinetobacter species.4, 10, 34, 
35 
6 
 
 Cultures are strongly recommended, particularly in patients at risk for infection by drug 
resistant (DR) pathogens, for consequent antibiotic therapy adjustment, aiming at maximizing its 
effect in the involved pathogens while minimizing selective pressure.4, 7, 10 This is particularly in HCA-
IAIs and HA-IAIs in which the antibiotic susceptibility testing is endorsed to adjust empirical antibiotic 
therapy.7, 25, 36  
 Even though it has been recorded that bacteriological cultures have minor influence on the 
progress of treatment of frequent diseases like appendicitis, in this period of extensive DR pathogens 
implicated in hospital and community-acquired infections, the danger of resistance is a cause of 
leading apprehension that cannot be neglected.4, 10 
 
 
Resistance to antibiotic therapy 
 
 In various regions, there is an emerging resistance to elected antibiotics among community-
acquired strains of gram-negative pathogens, including a broad predominance of 
ampicillin/sulbactam-resistant Escherichia coli globally, fluoroquinolone-resistant Escherichia coli in 
Latin America and East Asia, and regions with grand prevalence of enhanced-spectrum b-lactamase-
producing strains of Klebsiella species and Escherichia coli.14, 37 A relatively greater predominance, in 
some populations and communities, of more-resistant non-enteric gram-negative pathogens, such 
as Pseudomonas aeruginosa, will influence the choice of suitable empiric antibiotic therapy.10, 14 
 This has led to the recommendation that when 10-20% or more isolates from a usual 
community intra-abdominal pathogen shows resistance to a specific antibiotic, its use should be 
refrained.14 
 The range of pathogens implicated in hospital-acquired infections is much vaster. In the past 
two decades, the prevalence of hospital-acquired infections caused by DR pathogens has raised 
seriously, perhaps in relation with the rising levels of antibiotic exposure and escalating recurrence 
of patients with co-morbidities, such as augmented severity of chronic illness, higher age, extension 
of organ injury, low albumin levels, poor nutritional state, immunodepression and the existence of 
malignancy.4, 13 Infections by resistant pathogens, especially hospital-acquired are associated with 
increased risk of treatment failure and death.25, 38-40 
 Even though the transmission of multidrug-resistant (MDR) pathogens is most usually 
detected in acute care facilities, all healthcare environments are disturbed by the development of 
DR microorganisms.4  
 Risk factors, such as prior antibiotic therapy (for more than 48 hours in the previous two 
weeks) or during the prior three months, hospital stay’s duration or reoperation hiatus greater than 
five days, were linked to the development of IAIs by MDR pathogens.7, 41, 42 
 Furthermore, the major resistance issue of IAIs is presented by ESBL-producing 
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Enterobacteriaceae that are dangerously widespread in HA-IAIs and regularly noticed in CA-IAIs, 
even if in a lower frequency.4, 7, 10, 13 
 The Study for Monitoring Antimicrobial Resistance Trends (SMART) has monitored the in 
vitro susceptibility patterns of clinical Gram-negative bacilli to antimicrobial agents collected 
worldwide from IAIs since 2002. Hawser et al. described an increase in resistance rates of intra-
abdominal pathogens in Europe and the consequent decline of the number of available alternatives 
for the empirical treatment of IAIs.4, 43 
 Even if a diversity of factors can boost the danger of selection for ESBL producers, the most 
important determinants involve previous antibiotics’ exposure (particularly third generation 
cephalosporins) and co-morbidities involving simultaneous antibiotic therapy.4, 6, 13 
 Bacteria generating Klebsiella pneumoniae carbapenemases (KPCs) are quickly arising as a 
main origin of multi-resistant infection around the globe.4, 10 The late rise of carbapenem resistance 
in association with Enterobacteriaceae present a significant danger to hospitalized patients and a real 
challenge for clinical treatment.4 
 Along with hydrolyzing carbapenems, KPC-producing strains are frequently resistant to 
diverse alternative antibiotics, and competent treatment of these adaptable microorganisms has 
accordingly evolve into a serious obstacle for clinicians in acute care settings.4 KPC-producing 
bacteria have become prevalent in hospital-acquired infections, particularly in patients with prior 
exposure to antibiotics.4 
 Moreover, Pseudomonas aeruginosa and Acinetobacter baumannii have presented disquieting 
rates of expanded resistance to diverse antibiotics in hospitals and healthcare facilities around the 
world. Both pathogens are naturally resistant to various antibiotics and can acquire supplementary 
resistances to alternative valuable antibiotics.4, 6, 10 
 In the class of MDR gram-positive bacteria, Enterococci last a substantial challenge4. 
Empirical coverage of Enterococci is not advocated in CA-IAIs.4, 6, 7, 13, 31 Studies have proved that 
coverage facing Enterococci provides minor therapeutic advantage.4, 31 
 MRSA is another MDR gram-positive nosocomial microorganism acknowledged to induce 
serious morbidity and mortality around the world.4, 6 
 Even though community-acquired MRSA has been noted in other placings, there are no 
systematic data recorded in studies supporting the presence of MRSA in CA-IAIs.4, 10, 44 
 HA-IAIs should not be managed empirically for MRSA excepting in patients with record of 
past infections by this pathogen or in case of considering that the infection is related to MRSA.4, 6 
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Consequences of antibiotics misuse  
 
 There is evidence that inadequate and/or delayed antibiotic therapy is associated with 
treatment failure and increased mortality.2, 13, 14, 18, 25, 28, 30, 45-49  
 The sensitive equilibrium between the enhancement of empirical antibiotic therapy, which 
was proved to promote better clinical results, and the decline of needless antimicrobial overuse, 
which has been linked to the increasing development of MDR pathogens, is invariably needed when 
treating infections.10, 13, 50  
 Furthermore, needless wide coverage and excessively extended antibiotic therapy is 
associated with patient- and agent-specific toxicities of therapy, as well as superinfection by 
Clostridium difficile and organ damage.6, 8, 10, 14, 51 
 The use of antibiotics impacts not only the individual recipient, but also others that may be 
colonized or infected by resistant bacteria.50, 52 The gain of constitutionally resistant pathogens and 
selective pressure for resistance in the unit, hospital or community is of rising consideration.10, 14, 31, 
53, 54 It was considered a major public health issue and a danger for the future of healthcare by the 
World Health Organization (WHO) and the European Community (EC).18, 50, 52, 55-57  
 The main promoter of antibiotic resistance is the selective pressure induced by the use of 
antimicrobials, being the antibiotic overuse in humans and food-producing animals the major 
causes.56 Discoveries suggest that 80% of all antimicrobial are intended for food-producing animals, 
advocating for a better surveillance of agricultural and veterinary practises.56, 58 
 Antibiotic use in food animal production is frequent in several countries, including the 
United States of America (USA), where there is no control of antibiotic use in food-producing 
animals. European Union (EU) banned the use of nontherapeutic antibiotics of human importance 
to farm animals in 2006.55, 56  
 There is an essential need to develop new antimicrobial agents for the treatment of patients 
given the colonization of hospitalized patients with resistant microorganisms.31, 50 Since 1987, there 
have been no effective discoveries of new antibiotic classes.56   
 Due to the limited development of new antibiotics, particularly for gram-negative 
microorganisms, the careful use of antibiotic therapy is essential to hold the resistance rates and 
preserve the existent antibiotics.10, 52, 55, 57  
 Antimicrobial stewardship programs (ASP) can promote a better use of antibiotic therapy, 
de-escalation and reduce unsuitable prolonged durations of treatment,8, 18 being vital to hold and 
control resistance.10, 52, 57 They are also important to promote public understanding of the danger 
of antimicrobial resistance.52, 56  
 In light of the promising complexity of choosing suitable antibiotic therapy, local and regional 
protocols must be settled on the support of community root, patient comorbidities, clinical severity, 
existence of recorded beta-lactam allergy and by assessing local bacterial resistance data, which must 
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be developed by multidisciplinary teams (anesthetists-intensive care physicians, microbiologists, 
surgeons, infectious disease specialists and pharmacists).7, 8 Published articles have proven an 
improvement in antibiotic prescription practices after the implementation of antibiotic prescription 
protocols.18, 56, 59 
 The misuse of antibiotics is a leading worldwide issue with an extensive economic influence 
on rising healthcare costs, due to the selection of MDR bacteria, culminating in extended hospital 
stay and a greater mortality, improving its use would probably lead to lower costs and better 
outcomes.4, 5, 10, 12, 30, 52  
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STUDY AIMS AND OBJECTIVS  
 
 This study was designed to assess the impact of the different classifications of IAIs in the 
selection of the best antibiotic therapy, considering the need of adequate empirical antibiotic therapy 
and public health need to preserve antibiotics. 
 The main objectives of the study are: 
- to identify independent risk factors for IAI by pathogens sensitive to the antibiotic scheme 
recommended for CA-IAI: non-pseudomonal cephalosporin or ciprofloxacin plus 
metronidazole or piperacillin/tazobactam; 
- to describe the microbiological profile associated with each classification; 
- to determine the discriminative power of each IAI classification to identify patients infected 
by a pathogen sensitive to the shorter spectrum antibiotic combination (non-pseudomonal 
cephalosporin or ciprofloxacin plus metronidazole); 
- to describe major prognostic factors associated with hospital mortality among the study 
population of patients with IAI. 
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MATERIALS AND METHODS 
 
 Retrospective cohort study developed at Hospital de Santo António, Centro Hospitalar do 
Porto, a tertiary care university hospital, including all adult patients (≥ 18 years old) discharged from 
the hospital with the diagnosis of IAI between 1st of January and 31st of October of 2016.  
 The study was approved by the local ethics committee (ref. 2017.226(195-DEFI/187-CES).  
 First selection of the patients was achieved using the International Statistical Classification 
of Diseases and Related Health Problems 9th revision (ICD-9) (appendix A). For selected patients, 
clinical file was reviewed to confirm inclusion criteria and data of interest retrieved (appendix B).  
 Exclusion criteria were: patients with anal/rectal pathology, infections caused by non-
bacterial pathogens (that is virus, fungus and protozoa), non-complicated appendicitis, tuberculosis 
and patients with negative or no culture results. 
 The following variables were collected: age, gender, functional status, previous 
comorbidities, hospital admission date, discharge date, place of acquisition of the infection 
(community-acquired, healthcare-associated or hospital-acquired), extent of infection 
(uncomplicated or complicated), localization of infection (appendix, biliary tract, colon, small 
intestine, stomach/duodenum or other), post-operative infection (perforation, suture dehiscence, 
tertiary peritonitis, undetermined or non-applicable), microorganism(s) isolated, location of the 
isolated pathogen, realization of blood cultures, blood cultures’ result, resistance of isolated 
pathogens, empirical therapy administered to the patient in the first 24 hours after diagnosis 
(antibiotic, daily dose, route of administration), change of the initial antibiotic therapy, reason of the 
changing, adequacy of the empirical antibiotic therapy, risk factors for healthcare-associated 
infections, previous colonization/infection by DR pathogen, previous antibiotic therapy (last 3 
months), previous hospital admission (last year), previous invasive procedures (last year) and 
residence in a long-term care facility or nursing home and outcome at hospital discharge (dead or 
alive).  
 Functional status was assessed by the Karnofsky Performance Status Scale (KPS)60  and 
previous comorbidities by the Charlson Comorbidity Index (CCI)61. The initial empirical antibiotic 
therapy was considered appropriate if all of the bacteria isolated from cultures were sensitive to at 
least one of the drugs administered.  
 The primary outcome of interest was infection by a pathogen sensitive to the following 
antibiotic scheme: non-pseudomonal cephalosporin or ciprofloxacin plus metronidazole. Secondary 
outcomes were sensitivity to piperacillin/tazobactam and hospital mortality. 
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Statistical analysis 
 
 Data were described with means and standard deviations (SD) for continuous variables or 
with medians and inter-quartile ranges (IQR) if they showed a skewed distribution. Categorical 
variables were described with absolute frequencies and percentages. T-tests or Mann-Whitney-U 
tests were used to compare continuous variables. For categorical variables, these comparisons were 
performed using Pearson χ2 and Fisher’s exact tests. 
 All variables potentially associated with pre-defined outcomes were studied through logistic 
regression. Those with a clear association in the univariate analysis (p < 0.1) were included in the 
multivariable analysis. The results of the multivariable models are expressed as odds ratio (OR) with 
95% confidence interval (CI95%) and p-values. The accuracy of the models was assessed by the area 
under receiver operating characteristics (AUROC) curve and calibration was tested using the 
Hosmer-Lemeshow goodness-of-fit test. The significance level was defined as p < 0.05.  
 Data were analyzed using Statistical Package for the Social Sciences (SPSS) version 25 for 
Windows (SPSS Inc., Chicago, IL, USA).  
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RESULTS 
 
 There were 1804 patients discharged from the hospital during the study period that met 
the ICD-9 established criteria. Of these, 154 met the inclusion criteria (figure 1). 
 
 
Patient and hospitalization characteristics  
 
 The 154 patients included in the study had a mean±SD age of 73±14 years and 52% were 
female; 112 (73%) need some help for daily activities defined by a KPS score < 70 and 31 (20%) 
patients had no comorbidities according to the CCI definitions (table I). 
 Median (IQR) hospital length of stay was 17 (10-29) days and hospital mortality rate was 
22% (n=34).  
 The following risk factors were associated with an IAI by pathogens sensitive to the 
recommended shorter spectrum antibiotic therapy (non-pseudomonal cephalosporin or 
ciprofloxacin plus metronidazole): male gender, previous antibiotic therapy and previous invasive 
procedures (table I). 
 In the multivariable analysis with the following antibiotic combination: non-pseudomonal 
cephalosporin or ciprofloxacin plus metronidazole as the dependent variable, the final model 
retained male gender with an adjusted OR (CI95%) = 2,612 (1,328-5,148) and previous invasive 
procedures in the last year with an adjusted OR (CI95%)= 0,424 (0,216-0,833). The area under the 
receiver operating characteristics (ROC) curve (CI95%) was 0,65 (0,57-0,74) (table II).  
 With piperacillin/tazobactam as the dependent variable, the multivariable analysis retained 
liver disease with an adjusted OR (CI95%) = 3,580 (1,126-10,879) and post-operative infections with 
an adjusted OR (CI95%) = 2,944 (1,096-7,908). The area under the ROC curve (CI95%) was 0,604 
(0,504-0,704) (table II). 
 
 
Intra-abdominal infections classification and microbiological results 
 
 In table III, the distribution of IAI according to different classifications along with the 
associated microbiological profile is shown. 
 Post-operative infection was observed in 19 (12%) patients, caused by suture dehiscence 
in 8 (5%) patients, perforation in 3 (2%) patients and undetermined or by other causes in 8 (5%) 
patients. 
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 Blood cultures were drawn in 122 (79%) patients, of those 69 (45%) were positive. Besides 
blood, pathogens were isolated from peritoneal fluid in 60 (39%), bile in 13 (8%), feces in 11 (7%), 
abscess in 9 (5%), biliary drainage fluid in 1 (1%) and pancreas drainage fluid in 1 (1%) 
 
 
Antibiotic therapy 
 
 Although non-pseudomonal cephalosporin or ciprofloxacin plus metronidazole is the 
shorter spectrum recommended antibiotic therapy for CA-IAI, it was administered to only one 
patient, but if it was administered to all patients, it would have been adequate in 54% of them.  
 Among the antibiotic agents administered, piperacillin/tazobactam was the most frequently 
used, in 123 (80%) patients, followed by metronidazole in 7 (5%) patients, imipenem plus cilastatin 
in 6 (4%) patients, ciprofloxacin in 5 (3%) patients and amoxicillin/clavulanic acid in 4 (3%) patients. 
Nevertheless, the sensitivity to piperacillin/tazobactam was exhibited in 105 (68%) patients.    
 The distribution of sensitive pathogens to the studied antibiotic regimens (non-
pseudomonal cephalosporin or ciprofloxacin plus metronidazole, or piperacillin/tazobactam), 
according to the different classifications is shown on table III. 
 The empirical antibiotic therapy was changed in 83 (54%) patients, of these the susceptibility 
profile of the isolated pathogen was the most frequent reason in 40 (48%) patients.  
 The initial antibiotic therapy was adequate in 98 (64%) patients: 60 (72%) with CA-IAIs, 26 
(56%) with HCA-IAIs and 12 (46%) with HA-IAIs (p=0,034). In uIAI, 17 (68%) patients had 
adequate initial antibiotic therapy and in cIAI 81 (63%) patients had it (p=0,620). There was no 
relation between the local of infection and the adequacy of the initial antibiotic therapy (p=0,628).   
 In patients with post-operative infections, a higher frequency of inadequate antibiotic 
therapy was observed (63% vs 33%, p=0,010).  
 
 
Prognostic risk factors in intra-abdominal infections 
 
  In the multivariable analysis with the hospital mortality as the dependent variable, the final 
model retained age ≥ 70 with an adjusted OR (CI95%) = 4,677 (1,260-17,358), solid tumor with an 
adjusted OR (CI95%)= 3,127 (1,183-8,266) and sensitivity to non-pseudomonal cephalosporin or 
ciprofloxacin plus metronidazole with an adjusted OR (CI95%) = 0,368 (0,138-0,980). 
 Factors significantly associated with hospital mortality were: KPS score <70, chronic kidney 
disease, the total score of CCI, localization of infection, polymicrobial flora and sensitivity to non-
pseudomonal cephalosporin or ciprofloxacin plus metronidazole (table IV).   
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DISCUSSION 
 
 The main finding of our study was the fact that none of the existent classifications had a 
good discriminative power to identify IAIs caused by pathogens sensitive to the current antibiotic 
treatment recommendations. This supports the poor utility of the existent classifications of IAI. 
 Independent risk factors for IAI caused by those pathogens was male gender, for which we 
cannot found an explanation or similar results in other published studies; and previous invasive 
procedures in the last year which were associated with IAI by pathogens not sensitive to the shorter 
antibiotic scheme recommended for CA-IAI, which has also been enlightened by other studies that 
linked previous invasive procedures with greater rates of colonization and infection with MDR 
pathogens.23 
 An alternative antibiotic scheme for CA-IAI is piperacillin/tazobactam, which is an antibiotic 
with a broader spectrum. Post-operative infections were associated with a higher sensitivity to this 
antibiotic therapy. This result cannot be explained by this study or the literature reviewed. Liver 
disease also showed an association with increased sensitivity to this antibiotic therapy. Sargenti et 
al.62 revealed that patients with liver disease have mainly HCA-IAIs and HA-IAIS, which are often 
caused by bacteria resistant to commonly used antibiotics, piperacillin/tazobactam might be an 
option for this group of patients.63 
 The fact that the discriminative power of the developed models based on the patient’s 
individual characteristics presented a better discriminative power than existing classifications of IAI 
suggests that a new classification that also includes patient’s individual risks would be more helpful 
for choosing initial antibiotic therapy adequately. 
 Our data reveled that age³70 years was associated to an increased hospital mortality, which 
is also supported by the conclusions of other studies.20 Higher age was also connected, by many 
studies, to a greater prevalence of DR pathogens, which has been implicated in an augmented 
mortality rate.38-40 Solid tumor was the one comorbidity that presented a connection with greater 
mortality, which can be clarified by the higher prevalence of DR pathogens that will result in an 
increased mortality rate.13, 38-40 Patients with pathogens sensitive to non-pseudomonal cephalosporin 
or ciprofloxacin plus metronidazole had an associated lower hospital mortality, in this study. This 
antibiotic scheme recommended for community-acquired infections is the shortest spectrum one, 
pathogens sensitive to this regimen are less resistant, having adequate antibiotic therapy more 
frequently and causing infection with lower severity, which can explain this association.  
 The distribution of IAIs according to the place of acquisition was distinctive when compared 
to various studies, in which the proportion of CA-IAIs fluctuated between 33% and 87%, and the 
ratio of HA-IAIs or HCA-IAIs oscillated between 13% and 67%.9, 20, 44, 64, 65 This difference can be 
explained by the fact that the majority of these analyses used a classification that not discriminate 
CA-IAI, HCA-IAI and HA-IAI, adding HCA-IAIs as part of CA-IAIs or HA-IAIs. In our study, the 
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discrimination in three instead of two groups of IAIs according to the place of acquisition presented 
a better performance, particularly when considering IAIs by pathogens sensitive to 
piperacillin/tazobactam. 
 A study by Swenson et al.65 recognized that colorectal (26,4%), liver or biliary (25,5%) and 
small bowel (18,1%) were the most common location of IAIs, which is different in proportion when 
compared with our study, but establishes consonance in the two most frequent locals (biliary tract 
and colon).   
 Previous antibiotic therapy was recognized in 25% of patients with cIAI, which is similar to 
the percentage observed by Huang et al.9 (27%). 
 The total score of CCI was associated with increased hospital mortality in accordance with 
the study by Montravers et al.20, that also revealed that the presence of one or more comorbidities 
had a predictive value for hospital mortality. 
 In our study, most of the patients had blood cultures taken (79%) and nearly half were 
positive (45%), which is similar to the results of Krobot et al.28 (43%), but considerably higher than 
the data observed by Montravers et al.20 (6%). Microbiological cultures, including blood cultures, in 
IAIs are extremely important to establish an adequate antibiotic therapy and should be collected in 
every patient with IAI.4, 7, 13 
 The distribution of isolated pathogens, in our study, was identical to other reports, being 
Escherichia coli the most frequent independently of the classification used.9, 20, 28, 44, 64, 66 The 
prevalence of monomicrobial IAIs (62%) was much superior by comparison to the studies by 
Claridge et al.66 (41%) and Shah et al.67 (33%).  
 A study by Montravers et al.20 noticed that amoxicillin plus clavulanic acid was the most 
frequent antibiotic therapy administered to patients with CA-IAIs and one of the two antibiotic 
therapies (in addition to piperacillin plus tazobactam) used in patients with nosocomial IAIs. This 
data contrasts with our study results, in which piperacillin plus tazobactam was the most frequent 
antibiotic therapy administered (80%) and amoxicillin plus clavulanic acid was used in 3% of patients 
with IAIs.  
 The antibiotic therapy adequacy results of our study were distinctive from the identified by 
Montravers et al.20: 72% vs 63% in patients with CA-IAIs; 56% in patients with HCA-IAIs and 46% 
in patients with HA-IAIs vs 67% in patients with nosocomial IAIs, respectively. However, the rate of 
inadequate antibiotic therapy (36%) is within the range described in similar studies: a scope between 
13% and 44%.28  
 In our study, there was no significant difference in hospital mortality between adequate and 
inadequate antibiotic therapy, which was also observed by Montravers et al.20, but opposed to other 
several studies.9, 14, 25 
 The hospital mortality observed in this study is higher than the described by Sartelli et al.44 
(22% vs 11%), but comparable to the results presented by Montravers et al.20: 22% vs 24% in CA-
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IAIs; 20% in HCA-IAIs and 27% in HA-IAIs vs 23% in nosocomial IAIs. 
 Our study has some limitations. Firstly, since it is a single-centered study, the analysis was 
based on local data and resistance patterns. Being a retrospective study, data collection was limited 
to the existing records. 
 Therefore, the results of this study must be interpreted prudently.  
 We have not found studies that investigated the discrimination of different classifications of 
IAI on the selection of the best antibiotic therapy, so we assume that our results could be of value 
to the clinicians on the field.   
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CONCLUSIONS 
 
 In our study, none of the existent classifications helped significantly in the identification of 
IAIs caused by pathogens sensitive to the current antibiotic treatment recommendations for CA-
IAI, which reinforces the poor utility of the existent classifications of IAI. 
 Probably, a new classification that adds patient’s risk factors might have a greater potential 
in distinguish IAIs by sensitive pathogens allowing a better choice of empiric antibiotic therapy, 
tailored to individual patients needs with the minimum selective pressure. 
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Figure 1. Flow diagram of the population selection process. (ICD-9, International Statistical 
Classification of Diseases and Related Health Problems 9th revision; IAI, intra-abdominal infection)  
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Table 1. General characteristics of the study population and risk factors for IAI by pathogens 
sensitive to the following antibiotic scheme: non-pseudomonal cephalosporin or ciprofloxacin plus 
metronidazole. (*, Fisher's exact test; AIDS, acquired immune deficiency syndrome; DR, drug-
resistant; OR, odds ratio) 
 
 
 
 
 
 Total IAI by susceptible 
pathogens 
p value Crude OR 
Age ≥	70, n (%) 101 (66) 52 (52) 0,874 0,948 
Male gender, n (%) 74 (48) 46 (62) 0,015 2.223 
Karnofsky Performance Status Scale < 70, n (%) 112 (73) 62 (55) 0,167 1,653 
Diabetes, n (%) 45 (29) 19 (42) 0,121 0,575 
Liver disease, n (%) 14 (9) 6 (43) 0,475 0,669 
Solid tumour, n (%) 45 (29) 23 (51) 0,894 0,954 
AIDS, n (%) 1 (1) 1 (100) 1,000* - 
Chronic kidney disease, n (%) 26 (17) 9 (35) 0,052 0,425 
Congestive heart failure, n (%) 11 (7) 7 (64) 0,537* 1,678 
Myocardial infarction, n (%) 10 (7) 7 (70) 0,331* 2,269 
Chronic obstructive pulmonary disease, n (%) 10 (7) 6 (60) 0,748* 1,419 
Peripheral vascular disease, n (%) 22 (14) 11 (50) 0,843 0,913 
Cerebrovascular accident/transient ischemic attack, n (%) 14 (9) 8 (57) 0,683 1,259 
Dementia, n (%) 11 (7) 3 (27) 0,120* 0,321 
Hemiplegia, n (%) 1 (1) 1 (100) 1,000* - 
Connective tissue disease, n (%) 2 (1) 1 (50) 1,000* - 
Leukemia, n (%) 3 (2) 1 (33) 0,608* 0,456 
Malignant lymphoma, n (%) 1 (1) 1 (100) 1,000* - 
Peptic ulcer disease, n (%) 4 (3) 3 (75) 0,621* 2,844 
Total score - Charlson Comorbidity Index, mean±SD 5±3 5±3 0.956 0,980 per point 
Residence in a long-term care facility or nursing home, n (%) 7 (5) 2 (29) 0,259* 0,349 
Previous colonization/infection by DR pathogen, n (%) 29 (19) 16 (55) 0,700 1,173 
Previous antibiotic therapy, n (%) 39 (25) 14 (36) 0,020 0,416 
Previous hospitalization, n (%) 82 (53) 37 (45) 0,070 0,555 
Previous invasive procedures, n (%) 78 (51) 34 (44) 0,028 0,407 
Post-operative Infection, n (%) 19 (12) 9 (47) 0,670 0.811 
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Table II. Discriminative power of each classification for intra-abdominal infection by pathogen 
sensitive to antibiotic scheme for treatment of CA-IAI. (AUROC, area under receiver operating 
characteristics; CI, confidence interval; ATB I, non-pseudomonal cephalosporin or ciprofloxacin plus 
metronidazole; ATB 2, piperacillin/tazobactam; CA-IAI, community-acquired intra-abdominal 
infection; HCA-IAI, healthcare-associated intra-abdominal infection; HA-IAI, hospital-acquired intra-
abdominal infection; uIAI, uncomplicated intra-abdominal infection; cIAI, complicated intra-
abdominal infection) 
 
Classification of intra-abdominal infection 
AUROC curve (95% CI) 
for ATB 1 p value 
AUROC curve (95% CI) 
for ATB 2 p value 
Place of acquisition: CA-IAI, HCA-IAI, HA-IAI 0.570 (0.480-0.661) 0.134 0.657 (0.562-0.751) 0.002 
Place of acquisition: CA-IAI and HA-IAI 0.540 (0.448-0.632) 0.391 0.586 (0.485-0.686) 0.087 
Extent of infection: uIAI or cIAI 0.606 (0.515-0.696) 0.024 0.501 (0.402-0.599) 0.989 
Local of infection 0.591 (0.500-0.681) 0.053 0.572 (0.475-0.668) 0.152 
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Table III. Distribution of IAI according to different classifications and associated microbiological 
profile. (ATB I, non-pseudomonal cephalosporin or ciprofloxacin plus metronidazole; ATB 2, 
piperacillin/tazobactam; CA-IAI, community-acquired intra-abdominal infection; HCA-IAI, 
healthcare-associated intra-abdominal infection; HA-IAI, hospital-acquired intra-abdominal infection; 
uIAI, uncomplicated intra-abdominal infection; cIAI, complicated intra-abdominal infection) 
 
Place of acquisition, n (%) CA-IAI, 83 (54) HCA-IAI, 45 (29) HA-IAI, 26 (17) 
Microbiological profile, n (%) 
Monomicrobial, 46 (55) 
E. coli, 19 (41) 
Klebsiella spp., 7 (15) 
E. faecium, 4 (19) 
Other, 16 (25) 
Polymicrobial, 37 (45) 
Monomicrobial, 32 (61) 
E. coli, 7 (22) 
Klebsiella spp., 7 (22) 
Clostridium spp, 6 (19) 
Other, 12 (37) 
Polymicrobial, 13 (29) 
Monomicrobial, 17 (65) 
E. coli, 4 (24) 
Klebsiella spp., 2 (12) 
E. faecium, 2 (12) 
Clostridium spp, 2 (12) 
Other, 7 (40) 
Polymicrobial, 9 (35) 
IAI by pathogens sensitive to ATB I, n (%)  50 (60) 20 (44) 10 (40) 
IAI by pathogens sensitive to ATB II, n (%) 66 (80) 27 (60) 12 (46) 
 
Extent of infection, n (%) uIAI, 25 (16) cIAI, 129 (84) 
Microbiological profile, n (%) 
Monomicrobial, 15 (60) 
Clostridium spp, 9 (60) 
E. coli, 2 (13) 
E. faecium, 2 (13) 
Other, 2 (13) 
Polymicrobial, 10 (40) 
Monomicrobial, 80 (62) 
E. coli, 28 (35) 
Klebsiella spp., 16 (20) 
E. faecium, 8 (10) 
Other, 28 (35) 
Polymicrobial, 49 (38) 
IAI by pathogens sensitive to ATB I, n (%) 5 (20) 75 (60) 
IAI by pathogens sensitive to ATB II, n (%) 17 (68) 88 (68) 
 
Local of infection, n (%) Biliary Tract, 78 (51) Colon, 43 (28) Other, 33 (21) 
Microbiological profile, n (%) 
Monomicrobial, 54 (69) 
E. coli, 23 (43) 
Klebsiella spp., 13 (24) 
E. faecium, 7 (13) 
Other, 35 (45) 
Polymicrobial, 24 (31) 
Monomicrobial, 21 (49) 
Clostridium spp, 11 (52) 
E. coli, 3 (14) 
E. faecium, 2 (10) 
Other, 5 (24) 
Polymicrobial, 22 (51) 
Monomicrobial, 20 (60) 
Polymicrobial, 13 (40) 
IAI by pathogens sensitive to ATB I, n (%) 42 (54) 20 (47) 18 (55) 
IAI by pathogens sensitive to ATB II, n (%) 51 (65) 32 (74) 22 (67) 
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Table IV. Risk factors for hospital mortality. (*, Fisher's exact test; AIDS, acquired immune 
deficiency syndrome; DR, drug-resistant; OR, odds ratio; ATB I, non-pseudomonal cephalosporin or 
ciprofloxacin plus metronidazole; ATB 2, piperacillin/tazobactam) 
 
 Total 
Hospital 
mortality p value Crude OR 
Age ³ 70, n (%) 101 (66) 27 (27) 0,055 2,398 
Male gender, n (%) 74 (48) 13 (18) 0,194 0,599 
Karnofsky Performance Status Scale < 70, n (%) 112 (73) 20 (18) 0,042 0,435 
Diabetes, n (%) 45 (29) 10 (22) 0,978 0,988 
Liver disease, n (%) 14 (9) 4 (29) 0,512* 1,467 
Solid tumor, n (%) 45 (29) 14 (31) 0,082 2,010 
AIDS, n (%) 1 (1) 0 (0) 1,000* - 
Chronic kidney disease, n (%) 26 (17) 10 (39) 0,027 2,708 
Congestive heart failure, n (%) 11 (7) 0 (0) 0,124* - 
Myocardial infarction, n (%) 10 (7) 1 (10) 0,461* 0,374 
Chronic obstructive pulmonary disease, n (%) 10 (7) 3 (30) 0,693* 1,562 
Peripheral vascular disease, n (%) 22 (14) 4 (18) 0,785* 0,756 
Cerebrovascular accident/transient ischemic attack, n (%) 14 (9) 0 (0) 0,041* - 
Dementia, n (%) 11 (7) 5 (46) 0,066* 3,276 
Hemiplegia, n (%) 1 (1) 0 (0) 1,000* - 
Connective tissue disease, n (%) 2 (1) 1 (50) 0,394* 3,606 
Leukemia, n (%) 3 (2) 2 (67) 0,123* 7,437 
Malignant lymphoma, n (%) 1 (0,6) 0 (0) 1,000* - 
Peptic ulcer disease, n (%) 4 (3) 0 (0) 0,576* - 
Total Score - Charlson Comorbidity Index, mean±SD 5±3 5±3 0,045 0,866 per point 
Residence in a long-term care facility or nursing home, n (%) 7 (5) 2 (29) 0,469* 1,484 
Previous colonization/infection by DR pathogen, n (%) 29 (19) 4 (14) 0,322* 0,507 
Previous antibiotic therapy, n (%) 39 (25) 11(28) 0,286 1,571 
Previous hospitalization, n (%) 82 (53) 19 (23) 0,727 1,146 
Previous invasive procedures, n (%) 78 (51) 18 (23) 0,644 1,200 
Post-operative Infection, n (%) 19 (12) 3 (16) 0,483 0,629 
Initial antibiotic therapy adequate, n (%) 98 (64) 21(21) 0,797 0,902 
Polymicrobial flora, n (%) 59 (38) 18 (31) 0,049 2,168 
Sensitive to ATB I, n (%) 80 (52) 12 (15) 0,030 0,417 
Sensitive to ATB II, n (%) 105 (68) 19 (18) 0,084 0,501 
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Positive blood cultures, n (%) 69 (57) 16 (15) 0,065 0,429 
Post-operative infection, n (%) 19 (12) 3 (16) 0,570* 1,590 
Place of acquisition – classification, n (%) 154 (100) 34 (22) 0,790 - 
Community-acquired, n (%) 83 (54) 18 (22) - 1,000 
Healthcare-associated, n (%) 45 (29) 9 (20) - 1,330 
Hospital-acquired, n (%) 26 (17) 7 (27) - 1,474 
Extent of infection – classification, n (%) 154 (100) 34 (22) 0,195* - 
Uncomplicated, n (%) 25 (16) 3 (12) - 1,000 
Complicated, n (%) 129 (84) 31 (24) - 2,320 
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APPENDIX 
Appendix A. ICD-9 selected codes 
 
ICD-9 code Designation 
001 Cholera disease 
002 Typhoid and paratyphoid fevers 
003 Other Salmonella infections 
004 Shigellosis 
005 Other poisoning (bacterial) 
008 Intestinal infections due to other organisms 
009 Ill-defined intestinal infections 
038.3 Septicemia due to anaerobes 
038.4 Septicemia due to other gram-negative organisms 
038.8 Other specified septicemias 
038.9 Unspecified septicemia 
540 Acute appendicitis 
562.1 Diverticula of colon 
567 Peritonitis and retroperitoneal infections 
568.89 Other specified disorders of peritoneum 
569.5 Abscess of intestine 
569.61 Infection of colostomy or enterostomy 
569.83 Perforation of intestine 
572.0 Acute and subacute necrosis of liver 
574.0 Calculus of gallbladder with acute cholecystitis 
574.1 Calculus of gallbladder with other cholecystitis 
574.3 Calculus of bile duct with acute cholecystitis 
574.4 Calculus of bile duct with other cholecystitis 
574.6 Calculus of gallbladder and bile duct with acute cholecystitis 
574.7 Calculus of gallbladder and bile duct with other cholecystitis 
574.8 Calculus of gallbladder and bile duct with acute and chronic cholecystitis 
575.0 Acute cholecystitis 
575.1 Other cholecystitis 
576.1 Cholangitis 
576.3 Perforation of bile duct 
577 Diseases of pancreas 
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